Tulane Cancer Center | Strategic Alliance Partners

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.

Palliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.

A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.

Prescott Deininger, PhD, Professor and Regents Distinguished Chair, director, Tulane Cancer Center, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, discusses how genetic instability plays a role in mutations that may lead to specific tumor types.

Emad Kandil, MD, Chief of Endocrine Surgery at the Tulane University School of Medicine, discusses advances in surgical procedures.

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.

Three-dimensional printers are on the cusp of revolutionizing the way every doctor practices medicine.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.